Contributors: Genetic Epidemiology Division, Cancer Research UK Clinical Centre; Saint James's University Hospital; Section of Cancer Genetics; Institute of cancer research; Academic Radiotherapy Unit; Dept of Medical Oncology, Division of Medicine; University of New South Wales Sydney (UNSW)-Prince of Wales Hospital Randwick; Dept of Haematology and Medical Oncology; Peter MacCallum Cancer Center; Princess Margaret Hospital; University of Toronto; Dept of Radiotherapy and Oncology; University hospital of Prague; Dept of Oncology; Rigshospitalet Copenhagen; Copenhagen University Hospital-Copenhagen University Hospital; Génétique oncologique (GO - UMR 8125); Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS); Service d'urologie; Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Onco-génétique; Département de médecine oncologique Gustave Roussy; Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR); Génétique épidémiologique et structures des populations humaines (Inserm U535); Epidémiologie, sciences sociales, santé publique (IFR 69); Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Sud - Paris 11 (UP11)-École des hautes études en sciences sociales (EHESS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM); Dept of Urological Oncology; Phillips university; Department of Urology; Klinikum Kassel GmbH; Department of Molecular Genetics and Department of Chemotherapy; National Institute of Oncology; Department of Medical Oncology; St James's hospital; Cancer Genetics Laboratory; University of Otago Dunedin, Nouvelle-Zélande; Departments of Clinical Cancer Research and genetics; Rikshospitalet-Radiumhospitalet Trust; Laboratory of Clinical Genetics; Institute of Clinical Oncology; Medical Oncology; University Hospital Basel Basel; Cancer Epidemiology; University of Leeds-Cookridge Hospital; Barts and The London Queen Mary's School of Medicine; Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics; National Cancer Institute Bethesda (NCI-NIH); National Institutes of Health Bethesda, MD, USA (NIH)-National Institutes of Health Bethesda, MD, USA (NIH); Depts of Medicine and Biostatistics and Epidemology; Abramson Family Cancer Research Institute-Perelman School of Medicine; University of Pennsylvania-University of Pennsylvania; Department of Preventive Medicine; Keck School of Medicine Los Angeles; University of Southern California (USC)-University of Southern California (USC); Cancer Research U.K. Genetic Epidemiology Unit; Strangeways Research Laboratory
نبذة مختصرة : A family history of disease is a strong risk factor for testicular germ cell tumour (TGCT). In order to identify the location of putative TGCT susceptibility gene(s) we conducted a linkage search in 237 pedigrees with two or more cases of TGCT. One hundred and seventy-nine pedigrees were evaluated genome-wide with an average inter-marker distance of 10 cM. An additional 58 pedigrees were used to more intensively investigate several genomic regions of interest. Genetic linkage analysis was performed with the ALLEGRO software using two model-based parametric analyses and a non-parametric analysis. Six genomic regions on chromosomes 2p23, 3p12, 3q26, 12p13-q21, 18q21-q23 and Xq27 showed heterogeneity LOD (HLOD) scores of greater than 1, with a maximum HLOD of 1.94 at 3q26. Genome-wide simulation studies indicate that the observed number of HLOD peaks greater than one does not differ significantly from that expected by chance. A TGCT locus at Xq27 has been previously reported. Of the 237 pedigrees examined in this study, 66 were previously unstudied at Xq27, no evidence for linkage to this region was observed in this new pedigree set. Overall, the results indicate that no single major locus can account for the majority of the familial aggregation of TGCT, and suggests that multiple susceptibility loci with weak effects contribute to the disease.
Processing Request
No Comments.